Stay updated on Acalabrutinib vs Ibrutinib in CLL Clinical Trial
Sign up to get notified when there's something new on the Acalabrutinib vs Ibrutinib in CLL Clinical Trial page.

Latest updates to the Acalabrutinib vs Ibrutinib in CLL Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe expected modernization of the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025, with API users still able to provide input beforehand.SummaryDifference1%
- Check21 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.4%
- Check28 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check35 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1.0%
- Check64 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check78 days agoChange DetectedThe page has been updated to include new identifiers for a clinical trial related to Chronic Lymphocytic Leukemia, while significant details about the study's design and inclusion/exclusion criteria have been removed.SummaryDifference12%
Stay in the know with updates to Acalabrutinib vs Ibrutinib in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Acalabrutinib vs Ibrutinib in CLL Clinical Trial page.